MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Gilead Sciences Inc.

Closed

SectorHealthcare

106.04 -0.46

Overview

Share price change

24h

Current

Min

105.83

Max

107.54

Key metrics

By Trading Economics

Income

530M

1.8B

Sales

29M

7.6B

P/E

Sector Avg

274.553

57.333

EPS

1.9

Dividend yield

3.02

Profit margin

23.557

Employees

17,600

EBITDA

-655M

3.1B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+11.04% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.02%

2.63%

Next Dividend date

26 cze 2025

Next Ex Dividend date

13 cze 2025

Market Stats

By TradingEconomics

Market Cap

8.7B

130B

Previous open

106.5

Previous close

106.04

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Gilead Sciences Inc. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 kwi 2025, 20:17 UTC

Earnings

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

11 lut 2025, 21:17 UTC

Earnings

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

24 kwi 2025, 20:08 UTC

Earnings

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences 1Q Rev $6.67B >GILD

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences: During 1Q Generated $1.8 Billion in Operating Cash Flow >GILD

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences: 1Q Lower Veklury (Remdesivir) and Oncology Sales Offset by Higher HIV and Liver Disease Sales >GILD

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences Sees 2025 EPS $5.65-EPS $6.05 >GILD

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences 1Q EPS $1.04 >GILD

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences 1Q EPS $1.04 >GILD

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences Sees FY EPS $5.65-EPS $6.05 >GILD

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences 1Q Total Liver Disease Sales $758M >GILD

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences 1Q Net $1.32B >GILD

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences Sees FY Adj EPS $7.70-Adj EPS $8.10 >GILD

24 kwi 2025, 20:02 UTC

Earnings

Gilead Sciences 1Q Rev $6.7B >GILD

11 kwi 2025, 09:30 UTC

Top News

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

19 mar 2025, 14:50 UTC

Top News

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28 lut 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 lut 2025, 22:13 UTC

Market Talk
Earnings

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11 lut 2025, 21:06 UTC

Earnings

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences Raises Dividend 2.6%>GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

Peer Comparison

Price change

Gilead Sciences Inc. Forecast

Price Target

By TipRanks

11.04% upside

12 Months Forecast

Average 117.16 USD  11.04%

High 140 USD

Low 89 USD

Based on 24 Wall Street analysts offering 12 month price targets forGilead Sciences Inc. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

24 ratings

18

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

104.7894 / 106.5Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Weak Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.